NCT02982941View on ClinicalTrials.gov

Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

May 22, 2019

Study Completion Date

May 22, 2019

Conditions
NeuroblastomaRhabdomyosarcomaOsteosarcomaEwing SarcomaWilms TumorDesmoplastic Small Round Cell Tumor
Interventions
DRUG

Enoblituzumab

enoblituzumab administered IV weekly for up to 96 weeks

Trial Locations (6)

19104

Children's Hospital of Philadelphia, Philadelphia

20892

National Cancer Institute, Center for Cancer Research, Bethesda

53792

University of Wisconsin, American Family Children's Hospital, Madison

77030

Texas Children's Hospital, Houston

94304

Lucile Packard Children's Hospital, Stanford, Palo Alto

98105

Seattle Children's, Seattle

Sponsors

Lead Sponsor

MacroGenics
All Listed Sponsors
lead

MacroGenics

INDUSTRY